Skip to main content
GutCited

Berberine para Gut Dysbiosis

D Pesquisa Existem apenas investigaciones preliminares (estudos laboratoriais, relatórios de casos).

Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

Conclusão

Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.

Key Study Findings

In Vitro
Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal …
Dose: None vs: Sulfasalazine; DSS-induced UC mice Outcome: UC treatment efficacy Efeito: Colon length 1.2x longer than sulfasalazine None

População: DSS-induced UC murine model

Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None vs: None Outcome: None Efeito: None None

População: None

Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None vs: Free berberine; DSS-induced UC model vs normal mice Outcome: DAI scores, inflammatory cytokines, gut microbiota Efeito: None <0.01 (DAI); <0.05 (cytokines)

População: DSS-induced UC mouse model (male KM mice)

Other
Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis.
Dose: None vs: DSS-induced colitis + periodontitis mouse models Outcome: Periodontal destruction and myeloid cell generation Efeito: None None

População: DSS-induced colitis with periodontitis mouse model

Key Statistics

2

Estudos

100

Participantes

↑

Positive

D

Nota

Referenced Papers

Inflammatory bowel diseases 2025 2 citações
Gut microbes 2023 108 citações
Current pharmaceutical design 2023 10 citações
Comprehensive Physiology 2021 21 citações
Biomedicine & pharmacotherapy … 2019 72 citações
Alternative therapies in … 2017 9 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:
500-1,500 mg/day in divided doses
siboprotocol:
500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
giantimicrobial:
500 mg twice daily

Limite superior: Generally well-tolerated up to 1,500 mg/day in divided doses

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Positive --
None -- Mixed --
None -- Mixed --
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Positive --
None 6 weeks Positive --

Melhor horário: With meals; divide doses throughout the day (do not take full daily dose at once)

Safety & Side Effects

Efeitos Colaterais Relatados

  • ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
  • ⚠ May cause uterine contractions (contraindicated in pregnancy)
  • ⚠ Headache
  • ⚠ Skin rash (rare)

Interações Conhecidas

  • ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
  • ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
  • ● Anticoagulants (may have additive blood-thinning effects)
  • ● Metformin (additive glucose-lowering effect; monitor closely)
  • ● Macrolide antibiotics (berberine inhibits CYP3A4)

Ingestão máxima tolerável: Generally well-tolerated up to 1,500 mg/day in divided doses

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.

References

  1. [1] Yue Fan et al.. Int J Mol Sci. 2025. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. doi:10.3390/ijms26125486 PubMed
  2. [2] Yalong Wang et al.. Colloids Surf B Biointerfaces. 2025. Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal barrier and gut microbiota. doi:10.1016/j.colsurfb.2024.114353 PubMed
  3. [3] Daniela Ciobârcă et al.. Pharmaceuticals (Basel). 2025. Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease. doi:10.3390/ph18020279 PubMed
  4. [4] Quintero Vargas Jael Teresa de Jesús et al.. Pharmaceuticals (Basel). 2025. Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. doi:10.3390/ph18020193 PubMed
  5. [5] Xinyi Kuang et al.. Inflamm Bowel Dis. 2025. Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis. doi:10.1093/ibd/izaf150 PubMed
  6. [6] Jingqi Sun et al.. Pharmaceutics. 2025. Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles. doi:10.3390/pharmaceutics17060778 PubMed
  7. [7] Xiaoyu Tao et al.. Phytomedicine. 2025. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment. doi:10.1016/j.phymed.2025.157185 PubMed
  8. [8] Jiahui Xu et al.. J Nutr Biochem. 2025. Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila. doi:10.1016/j.jnutbio.2025.110069 PubMed
  9. [9] Wenwen Tan et al.. Eur J Pharmacol. 2025. Oxyberberine alleviates fructose-induced hyperuricemia by modulating purine metabolism and gut microbiota. doi:10.1016/j.ejphar.2025.178061 PubMed
  10. [10] Takuya Inokuchi et al.. Arch Oral Biol. 2025. Phellodendron bark extract and berberine chloride suppress microbiome dysbiosis in a saliva-derived in vitro microcosm biofilm model. doi:10.1016/j.archoralbio.2025.106231 PubMed
  11. [11] Lin Yin et al.. Front Nutr. 2025. The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in polycystic ovary syndrome. doi:10.3389/fnut.2025.1700612 PubMed
  12. [12] Mengxia Wang et al.. Biomed Pharmacother. 2024. Integration of microbiome, metabolomics and transcriptome for in-depth understanding of berberine attenuates AOM/DSS-induced colitis-associated colorectal cancer. doi:10.1016/j.biopha.2024.117292 PubMed
  13. [13] Florentina Ionita-Radu et al.. Int J Mol Sci. 2024. Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature. doi:10.3390/ijms25084201 PubMed
  14. [14] Lisheng Chen et al.. Front Pharmacol. 2024. Elucidation of the mechanism of berberine against gastric mucosa injury in a rat model with chronic atrophic gastritis based on … doi:10.3389/fphar.2024.1499753 PubMed
  15. [15] Hao Yang et al.. Hepatol Commun. 2024. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. doi:10.1097/HC9.0000000000000381 PubMed
  16. [16] Yazhi Qi et al.. Front Microbiol. 2024. Total Alkaloids of Rhizoma Corydalis regulates gut microbiota and restores gut immune barrier to ameliorate cognitive dysfunction in diabetic rats. doi:10.3389/fmicb.2024.1456406 PubMed
  17. [17] Wenjia Wang et al.. Front Microbiol. 2024. Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice. doi:10.3389/fmicb.2024.1428327 PubMed
  18. [18] Devi Datt Joshi et al.. Indian J Microbiol. 2024. Relevance of Indian Traditional Herbal Brews for Gut Microbiota Balance. doi:10.1007/s12088-024-01251-4 PubMed
  19. [19] Zikai Wang et al.. Gut Microbes. 2023. Colorectal cancer and gut microbiota studies in China. doi:10.1080/19490976.2023.2236364 PubMed
  20. [20] Xiongjie Sun et al.. Biomed Pharmacother. 2023. Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism. doi:10.1016/j.biopha.2023.115430 PubMed
  21. [21] Haitao Chen et al.. Int J Biol Sci. 2023. Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. doi:10.7150/ijbs.81824 PubMed
  22. [22] Qiao Zhang et al.. J Ethnopharmacol. 2023. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity. doi:10.1016/j.jep.2022.116127 PubMed
  23. [23] Tessa Dehau et al.. Front Pharmacol. 2023. Berberine-microbiota interplay: orchestrating gut health through modulation of the gut microbiota and metabolic transformation into bioactive metabolites. doi:10.3389/fphar.2023.1281090 PubMed
  24. [24] Leila Khalili et al.. Int J Mol Sci. 2023. Effects of Berries, Phytochemicals, and Probiotics on Atherosclerosis through Gut Microbiota Modification: A Meta-Analysis of Animal Studies. doi:10.3390/ijms24043084 PubMed
  25. [25] Ayoub Amssayef et al.. Curr Pharm Des. 2023. Alkaloids as Promising Agents for the Management of Insulin Resistance: A Review. doi:10.2174/0113816128270340231121043038 PubMed
  26. [26] Takuma Okuda et al.. J Oral Biosci. 2023. An in vitro study of the effects of Phellodendron bark extract and berberine chloride on periodontal pathogenic bacteria in the … doi:10.1016/j.job.2022.11.003 PubMed
  27. [27] Jindong Zhang et al.. J Neurogastroenterol Motil. 2023. Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats. doi:10.5056/jnm22182 PubMed
  28. [28] Ting-Wei Zhu et al.. Clin Exp Pharmacol Physiol. 2023. Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome. doi:10.1111/1440-1681.13814 PubMed
  29. [29] Awad A Shehata et al.. Microorganisms. 2022. Probiotics, Prebiotics, and Phytogenic Substances for Optimizing Gut Health in Poultry. doi:10.3390/microorganisms10020395 PubMed
  30. [30] Mingyue Zhong et al.. Food Funct. 2022. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. doi:10.1039/d2fo01009g PubMed
  31. [31] Qiang Sun et al.. Phytomedicine. 2022. Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota. doi:10.1016/j.phymed.2022.154227 PubMed
  32. [32] Mei Yang et al.. Biomater Sci. 2022. An oral pH-activated "nano-bomb" carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative … doi:10.1039/d1bm01765a PubMed
  33. [33] Xueying Li et al.. Microbiol Spectr. 2022. Berberine Depresses Inflammation and Adjusts Smooth Muscle to Ameliorate Ulcerative Colitis of Cats by Regulating Gut Microbiota. doi:10.1128/spectrum.03207-22 PubMed
  34. [34] Yufan Dai et al.. Braz J Med Biol Res. 2022. The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in … doi:10.1590/1414-431X2022e12096 PubMed
  35. [35] Qinmei Li et al.. Pharmacol Res. 2021. Main active components of Jiawei Gegen Qinlian decoction protects against ulcerative colitis under different dietary environments in a gut microbiota-dependent … doi:10.1016/j.phrs.2021.105694 PubMed
  36. [36] Wanghui Jing et al.. Pharmacol Res. 2021. Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites. doi:10.1016/j.phrs.2020.105358 PubMed
  37. [37] Jin-Dong Zhang et al.. Acta Pharmacol Sin. 2021. Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation. doi:10.1038/s41401-020-00601-4 PubMed
  38. [38] Xiangbing Shu et al.. Front Pharmacol. 2021. Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation. doi:10.3389/fphar.2021.750826 PubMed
  39. [39] Zhe Han et al.. Front Immunol. 2021. The Potential Prebiotic Berberine Combined With Methimazole Improved the Therapeutic Effect of Graves' Disease Patients Through Regulating the Intestinal Microbiome. doi:10.3389/fimmu.2021.826067 PubMed
  40. [40] Phillip B Hylemon et al.. Compr Physiol. 2021. Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. doi:10.1002/cphy.c210024 PubMed
  41. [41] Pamela Senesi et al.. Int J Mol Sci. 2021. Diabetes Mellitus and Cardiovascular Diseases: Nutraceutical Interventions Related to Caloric Restriction. doi:10.3390/ijms22157772 PubMed
  42. [42] Priyankar Dey. Pharmacol Res. 2020. Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases. doi:10.1016/j.phrs.2020.105135 PubMed
  43. [43] Noriko Shinjyo et al.. J Integr Med. 2020. Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. doi:10.1016/j.joim.2020.01.004 PubMed
  44. [44] Priyankar Dey. Pharmacol Res. 2019. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. doi:10.1016/j.phrs.2019.104367 PubMed
  45. [45] Shi-Jun Yue et al.. Am J Physiol Endocrinol Metab. 2019. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. doi:10.1152/ajpendo.00256.2018 PubMed
  46. [46] Shi-Jun Yue et al.. Biomed Pharmacother. 2019. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. doi:10.1016/j.biopha.2019.109002 PubMed
  47. [47] Sheng Wang et al.. Sci Rep. 2019. Jatrorrhizine Balances the Gut Microbiota and Reverses Learning and Memory Deficits in APP/PS1 transgenic mice. doi:10.1038/s41598-019-56149-9 PubMed
  48. [48] Wang Anlu et al.. Pharmacol Res. 2019. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. doi:10.1016/j.phrs.2019.02.018 PubMed
  49. [49] Chenjie Qin et al.. Sci China Life Sci. 2018. Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis. doi:10.1007/s11427-017-9202-0 PubMed
  50. [50] Benjamin I Brown. Altern Ther Health Med. 2017. Nutritional Management of Metabolic Endotoxemia: A Clinical Review. PubMed

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.